The role of general nuclear medicine in breast cancer

Lacey R. Greene, BS, CNMT¹ & Deborah Wilkinson, MS, CNMT²

¹Faculty of Science, Charles Sturt University, Wagga Wagga, New South Wales, Australia
²Faculty of Health, Wheeling Jesuit University, Wheeling, West Virginia

Keywords
Bone scan, breast cancer, scintimammography, sentinel node, SPECT

Abstract
The rising incidence of breast cancer worldwide has prompted many improvements to current care. Routine nuclear medicine is a major contributor to a full gamut of clinical studies such as early lesion detection and stratification; guiding, monitoring, and predicting response to therapy; and monitoring progression, recurrence or metastases. Developments in instrumentation such as the high-resolution dedicated breast device coupled with the diagnostic versatility of conventional cameras have reinserted nuclear medicine as a valuable tool in the broader clinical setting. This review outlines the role of general nuclear medicine, concluding that targeted radiopharmaceuticals and versatile instrumentation position nuclear medicine as a powerful modality for patients with breast cancer.

Introduction
Worldwide, breast cancer is the most common cancer in women with ~1.68 million newly diagnosed cases in 2012.¹ Estimated incidence is increasing worldwide and reported highest in developed countries such as the United Kingdom (UK) and the United States of America (USA), with a notable increase in both Australia and New Zealand.¹ Many factors such as genetic predisposition; prior personal or familial history of breast or other cancers; endogenous (lifetime cycle of oestrogen levels) and exogenous (hormone replacement therapy) hormone levels; and age (age of greatest risk is between 40 and 59 years old in the USA) predispose women to a higher lifetime risk.² Modifiable environmental and lifestyle factors such as excessive alcohol consumption, obesity and physical inactivity have also contributed to increased risk of and death from breast cancer.¹,² Mortality attributed to breast cancer is currently the second leading cause of death for women in developed regions.¹

Globally, a 20% increase in frequency and 14% rise in mortality since 2008 support clinical approaches that both mitigate risk and increase early detection and treatment.¹ In the latter, tailored management using a multimodality approach is readily achievable when incorporating nuclear medicine technology in the diagnostic plan. Developments in instrumentation such as the high-resolution dedicated breast device coupled with the diagnostic versatility of conventional cameras have reinserted nuclear medicine as a valuable tool in the broader clinical setting. This review outlines the critical role of general nuclear medicine in the care of women with breast cancer including detection and stratification (malignant vs. benign), guiding treatment using sentinel node imaging, monitoring cardiotoxicity from therapeutic regimens and evaluating local and global progression or recurrence. In addition, a brief overview describing the role of positron emission tomography/computed tomography (PET/CT) is discussed.
Scintimammography

Scintimammography provides non-invasive in vivo characterisation of malignant from benign processes and is best used in clinical scenarios where the mainstay anatomic modalities mammography and ultrasound are limited.3,4 Targeted uptake improves diagnostic integrity and decreases the rate of false-positives commonly seen in anatomical imaging which, in turn, reduces unnecessary invasive procedures and biopsies.5–7 Technetium-99m (Tc-99m) sestamibi is the radiopharmaceutical of choice for single-photon studies in breast imaging due in part to an overall tumour to background ratio of 6:1.3,8,9 The recommended administered dose range is 740–1100 MBq (20–30 mCi), resulting in an absorbed dose between 40.0 and 55.5 mGy to the large intestine (critical organ), 20 mGy to the kidney, bladder wall, and gallbladder wall each, and 2 mGy to the breast (lowest dose).10 An effective dose (a summed entire body exposure estimate that is weighted based on tissue radiosensitivity) was estimated to be 5.9–9.4 mSv compared to 0.44 mSv for digital mammography.10 As much as 90% of Tc-99m sestamibi dose is localised to the dense mitochondria characteristic of malignant cells, with uptake dependent on regional blood flow, tumour angiogenesis, increased metabolism and driven by plasma membrane potentials and mitochondrial membrane potentials.9,11–14 Tumour efflux of Tc-99m sestamibi has been correlated with cellular expression of P-glycoprotein, a protective transmembrane protein pump found in cells that overexpress the multi-drug resistant gene.11 These findings are clinically relevant as Tc-99m sestamibi can provide an in vivo prediction of anticancer drug efficacy.11,13 Moreover, faster rates of Tc-99m sestamibi efflux have been associated with higher levels of P-glycoprotein expression.11

Uptake of Tc-99m sestamibi may be non-specific, for example, in sites of prior surgical intervention or inflammation, and as such increased perfusion to these sites may result in false-positives.9,12,15–17 False-positive uptake has also been associated with benign diseases such as hyper-proliferative breast disease and atypical hyperplasia.18 A higher predilection towards malignant transformation has been demonstrated with both pathologies, speculating that a false-positive finding in these patients may reflect premalignant potential.18,19

Nuclear medicine scintimammography employs a wide range of instrumentation applications. In recent years, conventional planar scintimammography has been enhanced by single-photon emission computed tomography (SPECT) and hybrid SPECT/CT.20 Hybrid SPECT/CT adds clinical value by co-registering physiologic with anatomical data to assist non-palpable lesion biopsies, radiotherapy planning and treatment follow-up.20,21 Dedicated small field of view (FOV) breast-specific gamma imaging (BSGI) devices have also emerged internationally.1,17,22–24

For both scintimammography and BSGI, planar (anterior, lateral, oblique) orientations are obtained 5–15 min post-injection.3,5,10 Lateral and oblique images are acquired as the patient lies prone with pendent breasts while supine positioning is employed for anterior, oblique and SPECT tomographic acquisitions.10 Image acquisition in both positions is preferred.10 Prone positioning better separates breast tissue from high radiopharmaceutical uptake in the myocardium and liver improving visualisation of breast activity by reducing photon scatter and improving image contrast.10 Additionally, enhanced evaluation of the chest wall, better outline of the breast contour and improved spatial resolution (decreasing breast to camera distance) are advantages of the prone position. Supine positioning improves visualisation of primary lesion and internal mammary or axillae involvement.10,17 Analogous to mammography, BSGI obtains two 10- min images in the craniocaudal and mediolateral oblique orientations per breast.9

Of great importance to patient diagnosis and prognosis is breast lesion size and palpability as small non-palpable lesions often indicate early disease. Characterising mammographically non-palpable and probably benign lesions as metabolically benign could obviate the need for a difficult biopsy procedure and instead support clinical observation.6 Conversely, given the high specificity of scintimammography, a positive scintigraphic finding would support recommending an invasive evaluation.6 While multiple studies confirmed the dedicated camera design combined with breast positioning during BSGI provided better detection of sub-centimetre and non-palpable lesions compared to scintimammography,21,25–28 overall sensitivity and specificity was 82% and 85%, respectively, showing no improvement over SPECT, which was 86% and 87% respectively.29

Indeed, the dedicated camera design of BSGI is highly sensitive for detecting local disease, but is limited in the broader clinical setting compared to planar, SPECT, and SPECT/CT cameras that can investigate regional, axial and global disease. For example, SPECT scintimammography allows simultaneous tomographic evaluation of axial lymph node involvement.7,25 A study assessing 80 confirmed breast cancer participants for nodal involvement highlighted an overall specificity of 97.5% and sensitivity of 85% using SPECT.7 At present BSGI does not allow accurate detection of axial lymph node involvement.25 Moreover, when available, a dual acquisition protocol (planar and SPECT) further enhances the diagnostic value of scintimammography as illustrated
in a study investigating the value of scintimammography in inconclusive triple diagnosis (mammography, ultrasound and fine-needle aspiration). Mathieu et al. showed planar had higher specificity compared to SPECT (79.5% vs. 67%), but the addition of a SPECT acquisition detected 20% more lesions than planar alone. Additionally in this cohort, SPECT-altered patient management in 49% of cases, 51% of whom received a cancer diagnosis suggesting SPECT may also have an impact on mortality rates.

**Sentinel Lymph Node Scintigraphy**

The most important prognostic factor for newly diagnosed patients with invasive breast cancer is axial nodal bed status, a characterisation that is also critical for determining appropriate treatment. Imaging modalities are generally neither sensitive nor specific for axillary staging and so nodal involvement must be explored surgically. Introduced as a less invasive alternative to traditional staging methods that often increase morbidity like axillary lymph node dissection (ALND), determining sentinel lymph node status via biopsy (SLNB) can predict nodal involvement with high accuracy.

Because the sentinel node is the initial relay receiving lymphatic drainage directly from the tumour, a histopathologically negative sentinel node implies that the ipsilateral nodal bed is free from metastatic disease. Sparing the healthy nodal bed reduces both cost and common comorbidities associated with ALND. An axillary recurrence rate of 0–2% is associated with negative sentinel node status.

Nuclear medicine planar (dynamic or static) and/or SPECT/CT sentinel node imaging using radiolabelled colloids provide surgeons with a visual map to guide accurate localisation of sentinel nodes and atypical drainage patterns. Identification of the sentinel node is crucial to the success of SLNB and with a detection rate between 94% and 100% preoperative sentinel node imaging is ideally suited for this purpose. For patients with multicentric and multifocal disease whose lymphatic drainage patterns may vary, sentinel node imaging and SPECT/CT of all tumours may provide a more accurate approach to map and biopsy sentinel nodes for staging.

Radiocolloid injection techniques vary and include periareolar (Fig. 1), peritumoural, subdermal, subareolar, intradermal, intratumoural and subcutaneous. The two most common injection sites are periareolar (superficial) by means of the richly lymphatic subareolar plexus, which generate quick visualisation of the drainage channels with high target count rates; or peritumoural (deep), which can trace accessory drainage patterns, specifically the intra-mammary chain seen in ~20–30% of patients. Evidence suggests the injection site is considered somewhat versatile because time-to-visualisation rates are apparently influenced rather than false-negative rates. Literature also suggests variable lymphatic drainage patterns affect the ability to predict which lymphatic vessels would drain the tumour and thus should be considered when choosing an injection technique. As a precaution, it can be debated that an injection in proximity to the primary tumour would best represent true lymphatic physiology. Identifying all possible lymphatic drainage patterns is critical to patient care and justifies the current trend towards peritumoural versus periareolar injections.

Lymphatic transport of radiocolloid particles after injection can be influenced by particle size and dose concentration. Adequate lymphatic migration of large colloid particles is hindered by their size often resulting in either delayed visualisation or non-visualisation of axillary sentinel nodes. Conversely, particles that are very small rapidly migrate and may not remain trapped in the sentinel node. Solvent volumes should be adjusted to injection technique so that lymphatic physiology is accurately represented. For example, smaller volumes are more suitable for peritumoural injections as increased pressure may cause leakage into the extravascular space that may then travel to adjacent lymphatic channels.

Planar acquisitions (Fig. 1) consistently provide preoperative sentinel node mapping and the addition of multimodality SPECT/CT further enhances this role. Oriented SPECT/CT slices offer surgeons precise anatomic localisation of nodal uptake, reducing the duration of the surgical procedure and improving biopsy accuracy (Fig. 2). Evidence also showed SPECT/CT can identify difficult to interpret drainage patterns and sentinel nodes not visualised on planar (such as parasternal nodes), which limits blind exploratory surgery. Patient positioning and acquisition parameters are crucial for accurate visualisation of lymphatic drainage patterns and marking sentinel nodes. Patient images, patient markings, and an audible gamma probe collectively aid surgeons in intraoperative identification of the radioactive sentinel node or nodes for excision.

**Tc-99m Multigated Radionuclide Angiography**

It is well documented across cancer research that the use of multidrug chemotherapy induces cardiac abnormalities and requires routine monitoring of left ventricular ejection fraction. Among the rapidly increasing
Figure 1. Sentinel node localisation study of the right breast showing four periareolar radiopharmaceutical injections oriented on anterior, right anterior oblique (RAO) and right lateral planar images. An intense focal uptake lateral to the injection sites is identified as well as faint uptake in three axillary lymphatic chain nodes. Image courtesy of Regional Imaging, a member of I-MED Network Radiology, Wagga Wagga, NSW.

Figure 2. Fused SPECT/CT images provide surgeons with a more accurate anatomical visualisation of the sentinel node with regard to the breast and axilla by depicting the precise location in the axillary area adjacent to the first and second rib saving valuable intraoperative time and increasing surgical confidence. SPECT, single-photon emission computed tomography. Image courtesy of Regional Imaging, a member of I-MED Network Radiology, Wagga Wagga, NSW.
variety of anti-cancer drugs used in breast cancer treatment, the anthracyclines and the monoclonal antibody trastuzumab, are the agents with well-known cardiotoxicity. Anthracycline chemotherapy causes cumulative dose-dependent cardiotoxicity with direct and irreversible cellular damage to myocytes, which can result in congestive heart failure and even cardiac death. Trastuzumab can induce high cardiotoxicity rates particularly when combined with anthracyclines. Additionally, radiation therapy and chemotherapy drugs are pericardial irritants and as such increase the risk of pericardial effusion complications, making early diagnosis critical to decrease primary or contributory associated deaths seen in ~86% of symptomatic cancer patients. Radiation-induced heart disease such as coronary artery disease, valvular disease, constructive pericarditis and myocardial dysfunction including congestive heart failure can significantly limit a patient’s quality of life. Thus, it is imperative to effectively ascertain the extent of a patient’s risk for a cardiac event. The standard method to detect cardiotoxicity and pericardial effusions is acquiring ejection fraction measurements performed prior to and post-chemotherapy treatment in breast cancer patients. Serial evaluation allows clinicians to monitor the patient’s cardiac response to treatment reducing the risk of chemotherapy-induced comorbidities.

Multigated radionuclide angiography (RNA) or equilibrium radionuclide angiography (ERNA) is regarded as the gold standard to measure cardiac function with high reproducibility and low inter-observer variability in patients undergoing chemotherapy. RNA is a non-invasive technique that uses Tc-99m pertechnetate-erythrocyte labeling to assess regional and global wall motion, ventricular systolic and diastolic function (both right and left ventricular ejection fractions), and ventricular volumes. Red blood cell labeling with Tc-99m pertechnetate is performed using in vivo, in vitro, or modified in vivo methods as described in the literature. For any given clinical situation, the selection of a blood pool agent will depend on the acceptable level of image quality, requirements for patient throughput, and the level of expertise of the technical staff. Patient acceptance may also influence product selection. For example, some patients may refuse in vitro labelled red blood cells based on religious beliefs regarding transfusions.

Following radiopharmaceutical administration, planar, SPECT or combination acquisitions are obtained. To visualise all left ventricular wall segments, positioning for planar acquisition includes anterior, lateral, and left anterior oblique (LAO) views with a caudal tilt to best isolate the left ventricle from the left atrium and facilitate accurate processing. Using electrocardiogram leads, images are simultaneously registered with the patient’s gated heartbeat to evaluate regional left ventricular wall motion and contractility. The final result is a series of cine images of the heart that provide a map of sequential contractions or phase imaging to precisely quantify left ventricular volume and visually assess dysynchrony. The addition of a SPECT-gated technique acquires serial three-dimensional images that better differentiate the left and right ventricles without any overlap to inclusively calculate left and right ventricular ejection fractions and assess regional wall motion.

Early detection of cardiotoxic findings on serial imaging allows timely intervention to prevent associated patient morbidity or mortalities from trastuzumab- and anthracycline treatment. Evaluation of global LV systolic function and diastolic performance indexes using RNA has proven effective for early assessment of functional changes after chemotherapy compared to baseline, emphasising that serial imaging is critical at all treatment stages to assess patient prognosis. A reduction in the peak fill rate as measured by multigated RNA indicates worsening diastolic function, a parameter that is often impaired before declining systolic function in anthracycline-induced cardiotoxicity and more importantly, is an early indication of compromised cardiac function. Small or moderate cases of pericardial effusions do not compromise LVEF but may induce comorbidities such as compromised breathing, induced chest pain and abdominal fullness, and difficulty swallowing. Visualisation of a photopenic U-halo on the anterior and LAO projections of an ERNA scan may indicate the initial stages of pericardial effusion and allow early intervention and treatment adjustments to potentially mitigate progression.

Whole Body Bone Scan in Metastatic Disease

Bone metastases are present in ~80% of women with metastatic disease highlighting the predilection of breast cancer cells to metastasise to bone. Once bone metastases are diagnosed, median survival is between 2.1 and 6 years. Additionally, patients may experience a deterioration in their quality of life from associated complications of metastatic disease. Consequently, initial staging and regular follow-up evaluations for restaging are critical to improving quality of life and survival. Whole body (WB) bone scanning is a relatively inexpensive and non-invasive examination that is recommended for accurate staging of disease burden and follow-up evaluation in symptomatic or high-risk patients.

WB bone scanning by means of planar, SPECT, and/or SPECT/CT is a powerful first-line staging and treatment
WB bone scintigraphy uses bone-seeking radiopharmaceuticals that localise to sites of increased perfusion and bony turnover characteristic of bone metastases thus making it a highly sensitive tool for detecting osteoblastic and lytic/sclerotic mixed lesions (Fig. 3). Adding cross-sectional data from SPECT has been shown to detect more lesions than planar and improve specificity particularly in the axial skeleton where lesion uptake is difficult to discriminate from trauma or degenerative uptake (Fig. 4). Moreover, incorporating hybrid SPECT/CT data can better evaluate abnormal tracer uptake in benign skeletal pathology such as degenerative changes or cysts (Fig. 5). Co-registered data can also ascertain lytic lesions, which if the reparative process is not induced will appear cold on planar images and thus difficult to detect. A study by Iqbal et al. found an incremental improvement from 6.1% to 78.8% in the diagnostic accuracy of characterising vertebral metastases when adding SPECT/CT data to planar. The prognostic value of co-registered SPECT/CT can be noted in the results of a recent trial that down-staged 33.8% and up-staged 2.1% of breast cancer patients when compared to planar and SPECT bone scan.

Assessing systemic (chemotherapy or hormone therapy) or local (radiotherapy) treatment response is an area where nuclear medicine can excel. WB bone scanning provides earlier and more representative information as it depicts the body’s physiologic response to therapeutic interventions and often offers better prognostic value than an anatomical response. In some instances, bone scintigraphy may highlight an osteoblastic bone reaction commonly referred to as the bone ‘flare phenomenon.’
characterised by increased radiotracer uptake as a result of a therapeutic increased osteoblastic activity denoting healing bone.74 Flare is visualised on the WB bone scan as an exaggerated appearance of disease that is either representative of healing bone or previously invisible lesions.74 In either instance, visualisation of the flare response on bone scintigraphy may provide valuable prognostic information indicative of healing or progression of disease.

**Positron Emission Tomography/Computed Tomography**

In the United States, oncologic studies accounted for ~94% of the estimated 1.5 million PET/CT procedures performed in 2011.75 The tumour-avid glucose analog F-18 fluoro-2-deoxyglucose (F-18 FDG) has gained widespread acceptance as a marker of cellular metabolism providing insight into cancer physiology at the molecular level.76 The ability of PET/CT to accurately stage WB metastatic disease as well as quantify and evaluate therapeutic response has significantly impacted and tailored the care breast cancer patients receive.76,77

High sensitivity and specificity best appropriate PET/CT for detecting distant metastases as the system may not adequately resolve small primary breast lesions or axillary nodal regions.78,79 Currently under investigation to address this limitation, dedicated positron emission mammography (PEM) devices were designed to improve detection of small primary lesions by maximising system spatial resolution.80 PET/CT is comparable to and in some instances may outperform whole body bone scan (WBBS) in the detection of breast cancer metastases to

![Figure 4.](image-url) Figure 4. (B) SPECT images show intense focal uptake in the iliac crest of the left pelvic bone in the area near the anterior superior iliac spine and the posterior superior iliac spine near the left sacroiliac joint as visualised on the WBBS. (A) CT images demonstrate underlying sclerosis and distorted bony outline in the corresponding areas. (C) Fused SPECT/CT images clearly identify these areas as consistent with metastatic disease. SPECT, single-photon emission computed tomography; WBBS, whole body bone scan. Image courtesy of Regional Imaging, a member of I-MED Network Radiology, Wagga Wagga, NSW.
bone, showing similar sensitivity but greater specificity as a result of improved metabolic and morphologic characterisation of osseous lesions.\textsuperscript{76,77,81}

F-18 FDG can also provide an earlier and more objective prediction and assessment of response in many therapeutic settings.\textsuperscript{77,79} Using a standardised protocol, serial standard uptake value (SUV) measurements are derived directly from tumour metabolic avidity and thus provide a semi-quantitative representation of cancer physiology over time.\textsuperscript{79} There is also a positive correlation between prognostically poor aggressive disease and a higher lesion SUV\textsubscript{\textit{max}}, including values obtained from osseous lesions.\textsuperscript{76,77} Novel positron-emitting radiopharmaceuticals designed to boost specificity by targeting oestrogen, progesterone, oestrogen growth factor and somatostatin receptors identified on breast tumours have also been explored by PET/CT.\textsuperscript{82,83} Tumour characterisation, tailored therapy investigations, disease burden extent and disease monitoring with serial imaging are facilitated by receptor-mediated molecular imaging.\textsuperscript{84}

**Conclusion**

Nuclear medicine fills a physiologic niche in medical imaging for cancer patients, providing information representative of function and is a fundamental component of disease diagnosis, treatment and prognosis. Specifically for breast cancer care, general nuclear medicine supplies diagnostic value at each stage of the disease and is considered first-line modality in multiple clinical scenarios. The versatility of gamma cameras equipped with SPECT and/or SPECT/CT are indeed a
suitable tool for patients in the broader clinical setting offering a very detailed look into the current physiologic state of the body structures and their functions. PET/CT has emerged as a powerful oncologic tool and with the advent of targeted radiopharmaceuticals is predicted to undergo a highly anticipated expansion in the management of breast cancer. In the full scope of physiologic breast cancer imaging, future studies should investigate multi-acquisition (planar and SPECT) and multi-modality (SPECT/CT) imaging to further recognise the added value of instrument hybridisation protocols and processes in nuclear medicine imaging.

Acknowledgements

The authors thank Matthew Haase, Nuclear Medicine Manager at Regional Imaging in Wagga Wagga, NSW for providing the supporting images. We also thank Basit Iqbal, MBBS, MS, and PhD Scholar at Charles Sturt University, Wagga Wagga, NSW for his assistance with image interpretation.

Conflict of Interest

The authors declare no conflict of interest.

References

1. International Agency for Research on Cancer. Breast cancer estimated incidence, mortality and prevalence worldwide in 2012. World Health Organization [updated 2012]. Available from: http://www.globocan.iarc.fr/Pages/fact_sheets_cancer.aspx (accessed 8 January 2015).
2. Shah R, Rosso K, Nathanson SD. Pathogenesis, prevention, diagnosis and treatment of breast cancer. World J Clin Oncol 2014; 5: 283–98.
3. Brem R, Rechtman L. Nuclear medicine imaging of the breast: a novel, physiological approach to breast cancer detection and diagnosis. Radiol Clin North Am 2010; 48: 1055–74.
4. Munnik Th, Nagengast WB, Brouwers AH, et al. Molecular imaging of breast cancer. Breast 2009; 18: S66–73.
5. Ferrara A. Nuclear imaging in breast cancer. Radiol Technol 2010; 81: 233–46.
6. Tiling R, Kebler M, Untch M, Sommer H, Linke R, Hahn K. Initial evaluation of breast cancer using Tc-99m sestamibi scintimammography. Eur J Radiol 2005; 53: 206–12.
7. De Cesare A, Giuseppe DV, Stefano G, et al. Single photon emission computed tomography (SPECT) with Technetium-99m sestamibi in the diagnosis of small breast cancer and axillary lymph node involvement. World J Surg 2011; 35: 2668–72.
8. Mettler F, Guiberteau M. Essentials of Nuclear Medicine Imaging, 6th edn. Mosby Elsevier, St. Louis, MO, 2012.
9. Specht JM, Mankoff DA. Advances in molecular imaging for breast cancer detection and characterization. Breast Cancer Res 2012; 14: 206–17.
10. Hendrick RE. Radiation doses and cancer risks from breast imaging studies. Radiology 2010; 257: 246–53.
11. Taillifer R. Clinical applications of 99mTc-sestamibi scintimammography. Semin Nucl Med 2005; 35: 100–15.
12. Jacobsson H. Single-photon-emission computed tomography (SPECT) with 99mTcTechnetium sestamibi in the diagnosis of small breast cancer and axillary node involvement. World J Surg 2011; 35: 2673–4.
13. Kong FL, Kim E, Yang D. Targeted nuclear imaging of breast cancer: status of radiotracer development and clinical applications. Cancer Biother Radiopharm 2012; 27: 105–12.
14. Lee J, Rosen E, Mankoff D. The role of radiotracer imaging in the diagnosis and management of patients with breast cancer: part 1 – overview, detection and staging. J Nucl Med 2009; 50: 569–81.
15. Nguyen BD, Roarke MC, Karstaedt PJ, Ingui CJ, Ram PC. Practical applications of nuclear medicine in imaging breast cancer. Curr Probl Diagn Radiol 2009; 38: 68–83.
16. Kim SJ, Kim IJ, Bae YT, Kim YK, Kim DS. Comparison of quantitative and visual analysis of Tc-99m MIBI scintimammography for detection of primary breast cancer. Eur J Radiol 2005; 53: 192–9.
17. Prekeges J. Breast imaging devices for nuclear medicine. J Nucl Med Technol 2012; 40: 71–8.
18. Waxman A. The role of 99mTc methoxyisobutylisonitrile in imaging breast cancer. Semin Nucl Med 1997; 27: 40–54.
19. Silbera S, Rohan T. Benign proliferative epithelial disorders of the breast: a review of the epidemiologic evidence. Breast Cancer Res Treat 2008; 110: 397–409.
20. Sergieva S, Alexandra E, Baitchev G, Parvanova V. SPECT–CT in breast cancer. Arch Oncol 2012; 20: 127–31.
21. Schillaci O, Danieli R, Filippi L, et al. Scintimammography with a hybrid SPECT/CT imaging system. Anticancer Res 2007; 27: 557–62.
22. Surti S. Radionuclide methods and instrumentation for breast cancer detection and diagnosis. Semin Nucl Med 2013; 43: 271–80.
23. Moadel RM. Breast cancer imaging devices. Semin Nucl Med 2011; 41: 229–41.
24. Fowler A. A molecular approach to breast imaging. J Nucl Med 2014; 55: 177–80.
25. Spanu A, Cottu P, Manca A, Chessa F, Sanna D, Madeddu G. Scintimammography with dedicated breast camera in unifocal and multifocal/multicentric primary breast cancer detection: a comparative study with SPECT. Int J Oncol 2007; 31: 369–77.
26. Spanu A, Farris A, Chessa F, et al. Planar scintimammography and PSECT in neoadjuvant chemo or
hormotherapy response evaluation in locally advanced primary breast cancer. *Int J Oncol* 2008; 32: 1275–83.

27. Spanu A, Chessa F, Sanna D, et al. Scintimammography with a high resolution dedicated breast camera in comparison with SPECT/CT in primary breast cancer detection. *Q J Nucl Med Mol Imaging* 2009; 53: 271–80.

28. Sun Y, Wei W, Yang HW, Liu JL. Clinical usefulness of breast-specific gamma imaging as an adjunct modality to mammography for diagnosis of breast cancer: a systemic review and meta-analysis. *Eur J Nucl Med Mol Imaging* 2013; 40: 450–63.

29. Xu HB, Li L, Xu Q. Tc-99m sestamibi scintimammography for the diagnosis of breast cancer: meta-analysis and meta-regression. *Nucl Med Commun* 2011; 32: 980–8.

30. Mathieu I, Mazy S, Willemart B, Destine M, Mazy G, Lonneux M. Inconclusive triple diagnosis in breast cancer imaging: is there a place for scintimammography? *J Nucl Med* 2005; 46: 1574–81.

31. Hindie E, Groheux D, Brenot-Rossi I, Rubello D, Moretti JL, Espie M. The sentinel node procedure in breast cancer: nuclear medicine as the starting point. *J Nucl Med* 2011; 52: 405–14.

32. Rahbar H, Partridge S, Javid S, Lehman C. Imaging axillary lymph nodes in patients with newly diagnosed breast cancer. *Curr Probl Diagn Radiol* 2012; 41: 149–58.

33. Hildebrandt M, Bartram P, Bak M, et al. Low risk of recurrence in breast cancer with negative sentinel node. *Dan Med Bul* 2011; 58: A4255.

34. Caruso G, Cipolla C, Costa R, et al. Lymphoscintigraphy with peritumor injection versus lymphoscintigraphy with subdermal periareolar injection of technetium-labeled human albumin to identify sentinel lymph nodes in breast cancer patients. *Acta Radiol* 2014; 55: 39–44.

35. Hayashida T, Jinno H, Sakata M, et al. Superiority of radioisotope over blue dye for sentinel lymph node detection in breast cancer. *Eur Surg Res* 2010; 44: 111–6.

36. Classe JM, Baffert S, Sigal-Zafrani B, et al. Cost comparison of axillary sentinel lymph node detection and axillary lymphadenectomy in early breast cancer. A national study based on a prospective multi-institutional series of 985 patients 'on behalf of the Group of Surgeons from the French Unicancer Federation. *Ann Oncol* 2012; 23: 1170–7.

37. Schmid SM, Myrick ME, Forrer F, et al. Sentinel lymph node biopsy in primary breast cancer: trust the radiolabeled colloid method and avoid unnecessary procedures. *Eur J Surg Oncol* 2011; 37: 211–6.

38. Somasundaram SK, Chicken DW, Waddington WA, Bomanji J, Ell PJ, Keshtgar MRS. Sentinel node imaging in breast cancer using superficial injections: technical details and observations. *Eur J Surg Oncol* 2009; 35: 1250–6.

39. Sun X, Liu JJ, Wang YS, et al. Roles of preoperative lymphoscintigraphy for sentinel lymph node biopsy in breast cancer patients. *Ipn J Clin Oncol* 2010; 40: 722–5.

40. Johnson M, Guidroz J, Smith B, et al. A single institutional experience of factors affecting successful identification of sentinel lymph node in breast cancer patients. *Surgery* 2009; 146: 671–7.

41. Ibusuki M, Yamamoto Y, Kawasoe T, et al. Potential advantage of preoperative three-dimensional mapping of sentinel nodes in breast cancer by a hybrid single photon emission CT (SPECT)/CT system. *Surg Oncol* 2010; 19: 88–94.

42. Schafsma BE, Verbeek FPR, Rietbergen DDD, et al. Clinical trial of combined radio- and fluorescence-guided sentinel lymph node biopsy in breast cancer. *Br J Surg* 2013; 100: 1037–44.

43. Brouwer OR, Vermeeran L, van der Ploeg IMC, et al. Lymphoscintigraphy and SPECT/CT in multicentric and multifocal breast cancer: does each tumour have a separate drainage pattern? *Eur J Nucl Med Mol Imaging* 2012; 39: 1137–43.

44. Aliakbarian M, Memar B, Jangjoo A, et al. Factors influencing the time of sentinel node visualization in breast cancer patients using intradermal injection of the radiotracer. *Am J Surg* 2011; 202: 199–202.

45. Moncayo V, Aarsvold J, Grant S, Bartley S, Alazraki N. Status of sentinel lymph node for breast cancer. *Semin Nucl Med* 2013; 43: 281–93.

46. Mariani G, Moresco L, Viale G, et al. Radioguided sentinel lymph node biopsy in breast cancer surgery. *J Nucl Med* 2001; 42: 1198–215.

47. Garcia-Manero M, Olartecoche B, Royo P. Different injection sites of radionuclide for sentinel lymph node detection in breast cancer: single institution experience. *Eur J Obstet Gynecol Reprod Biol* 2010; 153: 185–7.

48. Noushi F, Spillane AJ, Uren RF, et al. High discordance rates between sub-areolar and peri-tumoral breast lymphoscintigraphy. *Eur J Surg Oncol* 2013; 39: 1053–60.

49. Uren RF, Howman-Giles R, Chung DKV, et al. SPECT/CT scans allow precise anatomical location of sentinel lymph nodes in breast cancer and redefine lymphatic drainage from the breast to the axilla. *Breast* 2012; 21: 480–6.

50. Vermeeran L, van der Ploeg I, Olmos RA, et al. SPECT/CT for preoperative sentinel node localization. *J Surg Oncol* 2010; 101: 184–90.

51. Kraft O, Havel M. Sentinel lymph nodes and planar scintigraphy and SPECT/CT in various types of tumours. Estimation of some factors influencing detection success. *Nucl Med Rev Cent East Eur* 2013; 16: 17–25.

52. Thorley P, Bould M, Chowdhury F. Gated cardiac SPECT: can it be used for serial assessment of left ventricular function in oncology patients? *Nucl Med Commun* 2013; 34: 1137–40.
53. Lapinska G, Kozlowicz-Gudzinska I, Sackiewicz-Slaby A. Equilibrium radionuclide ventriculography in the assessment of cardiotoxicity of chemotherapy and chemoradiotherapy in patients with breast cancer. *Nucl Med Rev Cent Eur* 2012; 15: 26–30.

54. Jeyakumar A, DiPenta J, Snow S, et al. Routine cardiac evaluation in patients with early-stage breast cancer before adjuvant chemotherapy. *Clin Breast Cancer* 2012; 12: 4–9.

55. Geiger S, Lange V, Suhl P, Heinemann V, Stemmler HJ. Anticancer therapy induced cardiotoxicity: review of the literature. *Anticancer Drugs* 2010; 21: 578–90.

56. Cochet A, Quilichini G, Dygai-Cochet I, et al. Baseline diastolic dysfunction as a predictive factor of trastuzumab-mediated cardiotoxicity after adjuvant anthracycline therapy in breast cancer. *Breast Cancer Res Treat* 2011; 130: 845–54.

57. Lu C, Rasuekbuel P, Drew AK. Positive spillover effects of prescribing requirements increased cardiac testing in patients treated with trastuzumab for HER2+ metastatic breast cancer. *Intern Med* 2012; 42: 1229–35.

58. Basavaraju SR, Easterly CE. Pathophysiological effects of radiation on atherosclerosis development and progression, and incidence of cardiovascular complications. *Med Phys* 2002; 29: 2391–403.

59. de Gues-Oei LF, Mavinkurve-Groothuis AM, Bellersen L, Gotthardt M, Oyen WJ, Kapusta L, van Laarhoven HW. Scintigraphic techniques for early detection of cancer treatment-induced cardiotoxicity. *J Nucl Med* 2011; 52: 560–71.

60. Mar M, Kim E. False positive pericardial effusion due to breast attenuation on equilibrium radionuclide angiocardiography. *J Nucl Med Technol* 2011; 39: 105–10.

61. Callahan RJ. Radiolabeled red blood cells: methods and mechanisms, Volume 12, Lesson 1, Continuing Education for Nuclear Pharmacists and Nuclear Medicine Professionals. University of New Mexico Health Sciences Center, College of Pharmacy, Albuquerque, New Mexico, 2006.

62. Corbett JR, Akinboboye OO, Bacharach SL, et al. Equilibrium radionuclide angiocardiography. *J Nucl Cardiol* 2006; 13: 56–79.

63. Lancellotti P, Nkomo V, Badano L, et al. Expert consensus for multi-modality imaging evaluation of cardiovascular complications of radiotherapy in adults: a report from the European Association of Cardiovascular Imaging and the American Society of Echocardiography. *J Am Soc Echocardiogr* 2013; 26: 1013–32.

64. Martin TJ, Moseley JM. Mechanisms in the skeletal complications of breast cancer. *Endocr Relat Cancer* 2000; 7: 271–84.

65. Pires A, Borges U, Lopes-Costa P, Gebrim L, da Silva B. Evaluation of bone metastases from breast cancer by bone scintigraphy and positron emission tomography/computed tomography imaging. *Eur J Obstet Gynecol Reprod Biol* 2014; 180: 138–41.

66. Ben-Haim S, Israel O. Breast cancer: role of SPECT and PET in imaging bone metastases. *Semin Nucl Med* 2009; 39: 408–15.

67. Chen J, Zhu S, Xie XZ, et al. Analysis of clinicopathological factors associated with bone metastasis in breast cancer. *J Huazhong Univ Sci Technolog Med Sci* 2013; 33: 122–5.

68. Houssami N, Costelloe CM. Imaging bone metastases in breast cancer: evidence on comparative test accuracy. *Ann Oncol* 2011; 23: 834–43.

69. Palmedo H, Marx C, Ebert A, et al. Whole-body SPECT/CT for bone scintigraphy: diagnostic value and effect on patient management in oncological patients. *Eur J Nucl Med Mol Imaging* 2014; 41: 59–67.

70. Cook G, Fogelman I. Skeletal metastases from breast cancer: imaging with nuclear medicine. *Semin Nucl Med* 1999; 29: 69–79.

71. Whitman G, Strom E. Workup and staging of locally advanced breast cancer. *Semin Radiat Oncol* 2009; 19: 211–21.

72. Glendenning J, Cook G. Imaging breast cancer bone metastases: current status and future directions. *Semin Nucl Med* 2013; 43: 317–23.

73. Iqbal B, Currie G, Wheat J, Raza H, Ahmed B, Kiat H. Incremental value of SPECT/CT in characterizing solitary spine lesions. *J Nucl Med Technol* 2011; 39: 201–7.

74. Fink C, Hasan B, Deleu S, Pallis A, Baas P, O’Brien M. High prevalence of osteoblastic bone reaction in computed tomography scans of an European Organisation for Research and Treatment of Cancer prospective randomised phase II trial in extensive stage small cell lung cancer. *Eur J Cancer* 2012; 48: 3157–60.

75. IMVinfo.com. [homepage on the Internet]. IMV 2012 PET imaging market summary report [updated 2012 Aug 7]. Available from: http://www.imvinfo.com/user/documents/content_documents/def_dis/2012_08_07_13_51_48_43_IMV_PET2012_report_datasheet.pdf (accessed 7 January 2015).

76. Gallamini A, Zwarthoed C, Borra A. Positron emission tomography (PET) in oncology. *Cancers* 2014; 6: 1821–89.

77. Bourgeois A, Warren L, Chang T, Embry S, Hudson K, Bradley Y. Role of positron emission tomography/computed tomography in breast cancer. *Radiol Clin North Am* 2013; 51: 781–98.

78. Hong S, Li J, Wang S. 18FDG PET-CT for diagnosis of distant metastases in breast cancer patients. A meta-analysis. *Surg Oncol* 2013; 22: 139–43.

79. Bensch F, van Kruchten M, Lamerts L, Schroder C, Hospers G, Brouwers A, van Vugt M, de Vries E. Molecular imaging for monitoring treatment response in breast cancer patients. *Eur J Pharmacol* 2013; 717: 2–11.
80. Kalles V, Zografos GC, Provatopoulou X, Koulocheri D, Gounaris A. The current status of positron emission mammography in breast cancer diagnosis. *Breast Cancer* 2013; **20**: 123–30.

81. Rong J, Wang S, Ding Q, Yun M, Zeng A, Ye S. Comparison of 18 FDG PET-CT and bone scintigraphy for detection of bone metastases in breast cancer patients. A meta-analysis. *Surg Oncol* 2013; **22**: 86–91.

82. Linden HM, Dehdashti F. Novel methods and tracers for breast cancer imaging. *Semin Nucl Med* 2013; **43**: 324–9.

83. Sekar TV, Dhanabal A, Paulmurugan R. Imaging cellular receptors in breast cancers: an overview. *Curr Pharm Biotechnol* 2011; **12**: 508–27.

84. Mankoff D, Link J, Linden H, Sundararajan L, Krohn K. Tumor receptor imaging. *J Nucl Med* 2008; **49**: 149S–63S.